Skip to main content
Top
Published in: Clinical Rheumatology 2/2009

01-02-2009 | Brief Report

Complementary and alternative medicines in ankylosing spondylitis: a cross-sectional study

Authors: Simon M. Chatfield, Shyamali C. Dharmage, Anthony Boers, Belinda J. Martin, Russell R. C. Buchanan, Walter P. Maksymowych, Lionel Schachna

Published in: Clinical Rheumatology | Issue 2/2009

Login to get access

Abstract

Prevalence of dietary complementary and alternative medicine (CAM) and consultation with a CAM practitioner was examined in a cross-sectional study of 75 AS patients. Seventy one of 75 (94.7%) study participants reported previous or current CAM use. Among these AS patients, 44 (72.1%) reported dietary CAM use and 27 (36.0%) were seeing a CAM practitioner at the time of study. Of 89 dietary CAM, 50 (56.4%) were perceived to be of slight or no benefit, and only 10 (11.2%) were initiated by a CAM practitioner. Compared with non-users, current dietary CAM users were more likely to be female (OR 6.5; 95% CI, 1.8–23.9). Patients attending a CAM practitioner were more likely to have university education (OR 5.7; 95% CI, 1.5–21.9) and higher BASDAI (OR 1.3; 95%CI, 1.0–1.7). Despite low rates of perceived benefit, dietary CAM use and CAM practitioner attendance is common among AS patients.
Literature
2.
go back to reference van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J et al (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54:2136–2146PubMedCrossRef van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J et al (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54:2136–2146PubMedCrossRef
3.
go back to reference Jois RN, Gaffney K, Keat A (2007) Anti-tumour necrosis factor therapy for ankylosing spondylitis-unresolved issues. Rheumatology 46:899–901PubMedCrossRef Jois RN, Gaffney K, Keat A (2007) Anti-tumour necrosis factor therapy for ankylosing spondylitis-unresolved issues. Rheumatology 46:899–901PubMedCrossRef
4.
go back to reference Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275–2285PubMedCrossRef Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275–2285PubMedCrossRef
5.
go back to reference Rao JK, Mihaliak K, Kroenke K, Bradley J, Tierney WM, Weinberger M (1999) Use of complementary therapies for arthritis among patients of rheumatologists. Ann Intern Med 131:409–416PubMed Rao JK, Mihaliak K, Kroenke K, Bradley J, Tierney WM, Weinberger M (1999) Use of complementary therapies for arthritis among patients of rheumatologists. Ann Intern Med 131:409–416PubMed
6.
go back to reference Cronan TA, Kaplan RM, Posner L, Blumberg E, Kozin F (1989) Prevalence of the use of unconventional remedies for arthritis in a metropolitan community. Arthritis Rheum 32:1604–1607PubMedCrossRef Cronan TA, Kaplan RM, Posner L, Blumberg E, Kozin F (1989) Prevalence of the use of unconventional remedies for arthritis in a metropolitan community. Arthritis Rheum 32:1604–1607PubMedCrossRef
7.
go back to reference Buchbinder R, Gingold M, Hall S, Cohen M (2002) Non-prescription complementary treatments used by rheumatoid arthritis patients attending a community-based rheumatology practice. Intern Med J 32:208–214PubMedCrossRef Buchbinder R, Gingold M, Hall S, Cohen M (2002) Non-prescription complementary treatments used by rheumatoid arthritis patients attending a community-based rheumatology practice. Intern Med J 32:208–214PubMedCrossRef
8.
go back to reference Zochling J, March L, Lapsley H, Cross M, Tribe K, Brooks P (2004) Use of complementary medicines for osteoarthritis—a prospective study. Ann Rheum Dis 63:549–554PubMedCrossRef Zochling J, March L, Lapsley H, Cross M, Tribe K, Brooks P (2004) Use of complementary medicines for osteoarthritis—a prospective study. Ann Rheum Dis 63:549–554PubMedCrossRef
9.
go back to reference Herman CJ, Allen P, Hunt WC, Prasad A, Brady TJ (2004) Use of complementary therapies among primary care clinic patients with arthritis. Prev Chronic Dis 1:A12PubMed Herman CJ, Allen P, Hunt WC, Prasad A, Brady TJ (2004) Use of complementary therapies among primary care clinic patients with arthritis. Prev Chronic Dis 1:A12PubMed
10.
go back to reference Cronan TA, Kaplan RM, Kozin F (1993) Factors affecting unprescribed remedy use among people with self-reported arthritis. Arthritis Care Res 6:149–155PubMedCrossRef Cronan TA, Kaplan RM, Kozin F (1993) Factors affecting unprescribed remedy use among people with self-reported arthritis. Arthritis Care Res 6:149–155PubMedCrossRef
11.
go back to reference Moore AD, Petri MA, Manzi S, Isenberg DA, Gordon C, Senecal JL et al (2000) The use of alternative medical therapies in patients with systemic lupus erythematosus. Trination Study Group. Arthritis Rheum 43:1410–1418PubMedCrossRef Moore AD, Petri MA, Manzi S, Isenberg DA, Gordon C, Senecal JL et al (2000) The use of alternative medical therapies in patients with systemic lupus erythematosus. Trination Study Group. Arthritis Rheum 43:1410–1418PubMedCrossRef
12.
go back to reference Fautrel B, Adam V, St-Pierre Y, Joseph L, Clarke AE, Penrod JR (2002) Use of complementary and alternative therapies by patients self-reporting arthritis or rheumatism: results from a nationwide canadian survey. J Rheumatol 29:2435–2441PubMed Fautrel B, Adam V, St-Pierre Y, Joseph L, Clarke AE, Penrod JR (2002) Use of complementary and alternative therapies by patients self-reporting arthritis or rheumatism: results from a nationwide canadian survey. J Rheumatol 29:2435–2441PubMed
13.
go back to reference Haugen M, Kjeldsen-Kragh J, Nordvag BY, Forre O (1991) Diet and disease symptoms in rheumatic diseases—results of a questionnaire based survey. Clin Rheumatol 10:401–407PubMedCrossRef Haugen M, Kjeldsen-Kragh J, Nordvag BY, Forre O (1991) Diet and disease symptoms in rheumatic diseases—results of a questionnaire based survey. Clin Rheumatol 10:401–407PubMedCrossRef
14.
go back to reference Ramos-Remus C, Watters CA, Dyke L, Suarez-Almazor ME, Russell AS (1999) Assessment of health locus of control in the use of nonconventional remedies by patients with rheumatic diseases. J Rheumatol 26:2468–2474PubMed Ramos-Remus C, Watters CA, Dyke L, Suarez-Almazor ME, Russell AS (1999) Assessment of health locus of control in the use of nonconventional remedies by patients with rheumatic diseases. J Rheumatol 26:2468–2474PubMed
15.
go back to reference van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368PubMedCrossRef van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368PubMedCrossRef
16.
go back to reference Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291PubMed Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291PubMed
17.
go back to reference Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMed Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMed
18.
go back to reference Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ et al (2003) Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 62:20–26PubMedCrossRef Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ et al (2003) Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 62:20–26PubMedCrossRef
19.
go back to reference Jones SD, Steiner A, Garrett SL, Calin A (1996) The Bath Ankylosing Spondylitis Patient Global Score (BAS-G). Br J Rheumatol 35:66–71PubMedCrossRef Jones SD, Steiner A, Garrett SL, Calin A (1996) The Bath Ankylosing Spondylitis Patient Global Score (BAS-G). Br J Rheumatol 35:66–71PubMedCrossRef
20.
go back to reference Australian bureau of statistics, Commonwealth of Australia. Socioeconomic indexes for areas (SEIFA) Volume 1.1. Australian bureau of statistics: Canberra, Australia, 2001 Australian bureau of statistics, Commonwealth of Australia. Socioeconomic indexes for areas (SEIFA) Volume 1.1. Australian bureau of statistics: Canberra, Australia, 2001
21.
go back to reference Feldman DE, Duffy C, De Civita M, Malleson P, Philibert L, Gibbon M et al (2004) Factors associated with the use of complementary and alternative medicines in juvenile idiopathic arthritis. Arthritis Rheum 51:527–532PubMedCrossRef Feldman DE, Duffy C, De Civita M, Malleson P, Philibert L, Gibbon M et al (2004) Factors associated with the use of complementary and alternative medicines in juvenile idiopathic arthritis. Arthritis Rheum 51:527–532PubMedCrossRef
22.
go back to reference MacLennan AH, Wilson DH, Taylor AW (1996) Prevalence and cost of alternative medicine in Australia. Lancet 347:569–573PubMedCrossRef MacLennan AH, Wilson DH, Taylor AW (1996) Prevalence and cost of alternative medicine in Australia. Lancet 347:569–573PubMedCrossRef
23.
go back to reference Sundstrom B, Stalnacke K, Hagfors L, Johansson G (2006) Supplementation of omega-3 fatty acids in patients with ankylosing spondylitis. Scand J Rheumatol 35:359–362PubMedCrossRef Sundstrom B, Stalnacke K, Hagfors L, Johansson G (2006) Supplementation of omega-3 fatty acids in patients with ankylosing spondylitis. Scand J Rheumatol 35:359–362PubMedCrossRef
24.
go back to reference Vecchio PC (1994) Attitudes to alternative medicine by rheumatology outpatient attenders. J Rheumatol 21:145–147PubMed Vecchio PC (1994) Attitudes to alternative medicine by rheumatology outpatient attenders. J Rheumatol 21:145–147PubMed
Metadata
Title
Complementary and alternative medicines in ankylosing spondylitis: a cross-sectional study
Authors
Simon M. Chatfield
Shyamali C. Dharmage
Anthony Boers
Belinda J. Martin
Russell R. C. Buchanan
Walter P. Maksymowych
Lionel Schachna
Publication date
01-02-2009
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 2/2009
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-008-1029-3

Other articles of this Issue 2/2009

Clinical Rheumatology 2/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.